Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01822522 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
A Phase 1 study of Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 20
- Study locations
NCT01822522 is a Phase 1 study of Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants, below the 176-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT01822522, a Phase 1 study of Advanced Malignant Solid Neoplasm and Metastatic Malignant Solid Neoplasm, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of cabozantinib s-malate in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment and human immunodeficiency virus. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- DRUG Cabozantinib S-malate
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
Study Locations (20)
California
- UC San Diego Moores Cancer Center - La Jolla
- UCLA Center for Clinical AIDS Research and Education - Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- UC San Diego Medical Center - Hillcrest - San Diego
New York
- Montefiore Medical Center-Einstein Campus - The Bronx
- Montefiore Medical Center-Weiler Hospital - The Bronx
- Montefiore Medical Center - Moses Campus - The Bronx
Texas
- Thomas Street Clinic - Houston
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center - Houston
- Ben Taub General Hospital - Houston
Washington
- Virginia Mason Medical Center - Seattle
- Harborview Medical Center - Seattle
- Fred Hutchinson Cancer Research Center - Seattle
Missouri
- Siteman Cancer Center at Washington University - St Louis
- Washington University School of Medicine - St Louis
Hawaii
- University of Hawaii Cancer Center - Honolulu
Louisiana
- Louisiana State University - Lafayette
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-06-21 |
| Est. Completion | 2021-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01822522
The ClinicalTrials.gov registry entry for NCT01822522 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 176-participant average among 108 other Advanced Malignant Solid Neoplasm trials with a reported enrollment target (80% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Advanced Malignant Solid Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Cabozantinib S-malate is the first listed.
NCT01822522 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT01822522 about?
NCT01822522 is a clinical study titled "Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus". This phase I trial studies the side effects and best dose of cabozantinib s-malate in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment and human immunodeficiency virus. Cabozantinib s-malate may stop the growth ...
What is the current status of trial NCT01822522?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-06-21. Estimated completion is 2021-05-12.
What conditions does trial NCT01822522 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, HIV Infection, Recurrent Malignant Solid Neoplasm, Unresectable Solid Neoplasm.
What interventions are being tested in trial NCT01822522?
The interventions under investigation include: Cabozantinib S-malate (DRUG), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01822522?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01822522 being conducted?
This trial has 20 study locations across California, Hawaii, Louisiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
Studying TAK-243 in Patients With Advanced Cancer
RECRUITING · Phase 1
-
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Advanced Malignant Solid Neoplasm
All registered trials for this condition
Metastatic Malignant Solid Neoplasm
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.